CMPS - Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
2024-07-08 10:11:19 ET
Summary
- COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN.
- The company addresses unmet mental health needs through psychedelic therapies.
- COMP360 showed promising results in Phase 2 trials for PTSD, with significant improvements in depression symptoms.
- Industry-wide regulatory uncertainties persist, highlighted by the FDA's recent decision against MDMA for PTSD.
- I believe CMPS is undervalued. Its substantial aggregate TAM and strategic collaborations bode well for potential FDA approval and commercialization.
...
Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies